Ohio State Navbar


Dr. Terence Williams Lab

Dr. Terence Williams, MD, PhD.
Associate Professor

Phone:  614-293-5557
Fax:      614-293-4440
Dr. Williams Research Page







Research Area

Radiation and chemotherapy resistance, cellular and DNA response to radiation, biologic markers for therapeutic response, molecular profiling, role of tumor microenvironment in therapy response, mouse modeling, human tissure research.

Research Summary

  Dr. Williams’ laboratory focuses on DNA damage response pathways and novel mechanisms of radiosensitization. In particular, the lab is focused on the molecular biology and genetics which govern response to treatment, particularly with chemotherapy and radiation. Knowledge of the genetics and molecular biology prior to treatment, and the manner in which activation of these biologic pathways changes after treatment, could potentially lead to identification of predictive biomarkers of response to therapy, or identify novel resistance pathways which could then be targeted to improve cancer control. Thus, the goals of current projects in the lab are to identify novel biomarkers of response to radiation in combination with other therapies, including chemotherapy or molecularly-targeted agents.

  Active Research Projects include: 

  • Investigating oncogene-mediated radioresistance (e.g. KRAS, BRAF)
  • Studying caveolins and caveolae-related endocytosis and their importance with regards to tumor progression and response to therapy
  • Rational development of novel therapeutic combinations of molecularly-targeted agents and radiation
  • Molecular profiling of GI and lung malignancies using systems-based approaches (e.g. miRNA, mRNA expression, methylation)
  • Novel DNA repair pathways and their relationship to cancer development and therapeutic response.


   Research is centered in the study of gastrointestinal (pancreatic, esophago- gastric, colorectal, and hepatobiliary) and thoracic (non-small cell lung cancer) malignancies, using pre-clinical modeling, with the goal of translating findings from pre-clinical studies to clinical trials to improve therapeutic efficacy, or develop prognostic/predictive signatures. Finally, additional laboratory interests include study of caveolar-mediated endocytosis in tumor cells, utilization of human tissues to perform molecular profiling to identify novel signatures that predicts clinical outcomes and response or novel targets, and studying the role of stroma in radiation response.